Apogee Therapeutics, Inc.
APGE
Rang in aandelen
#2337
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Aandeelprijs
$135.07
Laatst gesynchroniseerd: 2026-09-04
Marktkapitalisatie
$8.36B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
152.56%
Land
US
Handel Apogee Therapeutics, Inc. (APGE)
Categorie
Healthcare
Koersgeschiedenis voor Apogee Therapeutics, Inc. (APGE)
Hoogste slotkoers: $135.07 op 2026-09-01
Laagste slotkoers: $20.79 op 2023-07-01
Laagste slotkoers: $20.79 op 2023-07-01
Koersgeschiedenis van Apogee Therapeutics, Inc. van 2023 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 17.47% |
| 2025 | 60.85% |
| 2024 | 96.41% |
| 2023 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $761.12 | 8.18% |
CH
|
